{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T01:28:13Z","timestamp":1788917293308,"version":"build-2803163510"},"reference-count":28,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Urologic Oncology: Seminars and Original Investigations"],"published-print":{"date-parts":[[2022,1]]},"DOI":"10.1016\/j.urolonc.2021.03.024","type":"journal-article","created":{"date-parts":[[2021,6,4]],"date-time":"2021-06-04T03:19:23Z","timestamp":1622776763000},"page":"9.e1-9.e7","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":29,"title":["Intravesical sequential gemcitabine and docetaxel versus bacillus calmette-guerin (BCG) plus interferon in patients with recurrent non-muscle invasive bladder cancer following a single induction course of BCG"],"prefix":"10.1016","volume":"40","author":[{"given":"Ryan L.","family":"Steinberg","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vignesh T.","family":"Packiam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lewis J.","family":"Thomas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nathan","family":"Brooks","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Vitale","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah L","family":"Mott","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Trafford","family":"Crump","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William C.","family":"DeWolf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donald L","family":"Lamm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Max","family":"Kates","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. Eric","family":"Hyndman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashish M.","family":"Kamat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Trinity J.","family":"Bivalacqua","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenneth G.","family":"Nepple","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael A.","family":"O'Donnell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.urolonc.2021.03.024_bib0001","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1016\/j.eururo.2019.08.016","article-title":"European association of urology guidelines on non-muscle-invasive bladder cancer (TaT1 and carcinoma in situ)-2019 update","volume":"76","author":"Babjuk","year":"2019","journal-title":"European urology"},{"issue":"4","key":"10.1016\/j.urolonc.2021.03.024_bib0002","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1016\/j.juro.2016.06.049","article-title":"Diagnosis and treatment of non-muscle invasive bladder cancer: AUA\/SUO guideline","volume":"196","author":"Chang","year":"2016","journal-title":"J Urol"},{"issue":"5","key":"10.1016\/j.urolonc.2021.03.024_bib0003","doi-asserted-by":"crossref","first-page":"1915","DOI":"10.1016\/j.juro.2010.06.147","volume":"184","author":"Nepple","year":"2010","journal-title":"J Urol"},{"issue":"16","key":"10.1016\/j.urolonc.2021.03.024_bib0004","doi-asserted-by":"crossref","first-page":"1935","DOI":"10.1200\/JCO.2015.64.4070","article-title":"Definitions, end points, and clinical trial designs for non\u2013muscle-invasive bladder cancer: recommendations from the International Bladder Cancer Group","volume":"34","author":"Kamat","year":"2016","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.urolonc.2021.03.024_bib0005","doi-asserted-by":"crossref","first-page":"29","DOI":"10.3233\/BLC-159002","article-title":"Clarification of bladder cancer disease states following treatment of patients with intravesical BCG","volume":"1","author":"Lerner","year":"2015","journal-title":"Bladder Cancer."},{"issue":"2","key":"10.1016\/j.urolonc.2021.03.024_bib0006","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1016\/S0022-5347(17)43959-0","article-title":"Risks and benefits of repeated courses of intravesical bacillus Calmette-Guerin therapy for superficial bladder cancer","volume":"137","author":"Catalona","year":"1987","journal-title":"J Urol"},{"issue":"5","key":"10.1016\/j.urolonc.2021.03.024_bib0007","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1007\/s00345-006-0112-0","article-title":"Treatment options for BCG failures","volume":"24","author":"O'Donnell","year":"2006","journal-title":"World J Urol"},{"issue":"1","key":"10.1016\/j.urolonc.2021.03.024_bib0008","doi-asserted-by":"crossref","DOI":"10.1016\/j.urolonc.2019.05.018","article-title":"Contemporary oncologic outcomes of second induction course BCG in patients with nonmuscle invasive bladder cancer","volume":"38","author":"Daniels","year":"2020","journal-title":"Urol Oncol"},{"issue":"4","key":"10.1016\/j.urolonc.2021.03.024_bib0009","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1016\/j.urolonc.2005.11.026","article-title":"Final results from a national multicenter phase II trial of combination bacillus Calmette-Guerin plus interferon alpha-2B for reducing recurrence of superficial bladder cancer","volume":"24","author":"Joudi","year":"2006","journal-title":"Urol Oncol"},{"issue":"3","key":"10.1016\/j.urolonc.2021.03.024_bib0010","doi-asserted-by":"crossref","first-page":"227","DOI":"10.3233\/BLC-179018","article-title":"The BCG Shortage","volume":"3","author":"Messing","year":"2017","journal-title":"Bladder Cancer."},{"key":"10.1016\/j.urolonc.2021.03.024_bib0011","series-title":"BCG Shortage Info: American Urological Assocation","author":"Swanson","year":"2020"},{"issue":"5","key":"10.1016\/j.urolonc.2021.03.024_bib0012","doi-asserted-by":"crossref","first-page":"902","DOI":"10.1097\/JU.0000000000000688","article-title":"Multi-institution evaluation of sequential gemcitabine and docetaxel as rescue therapy for nonmuscle invasive bladder cancer","volume":"203","author":"Steinberg","year":"2020","journal-title":"J Urol"},{"issue":"15","key":"10.1016\/j.urolonc.2021.03.024_bib0013","doi-asserted-by":"crossref","first-page":"1401","DOI":"10.1056\/NEJMp1615697","article-title":"Ensuring access to injectable generic drugs-the case of intravesical BCG for bladder cancer","volume":"376","author":"Davies","year":"2017","journal-title":"NEJM"},{"key":"10.1016\/j.urolonc.2021.03.024_bib0014","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/j.urology.2020.08.004","article-title":"Contemporary treatment patterns for non-muscle-invasive bladder cancer: Has the use of radical cystectomy changed in the BCG shortage era?","volume":"147","author":"Tully","year":"2020","journal-title":"Urology"},{"issue":"3","key":"10.1016\/j.urolonc.2021.03.024_bib0015","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1097\/MOU.0000000000000739","article-title":"Treatment options and results of adjuvant treatment in nonmuscle-invasive bladder cancer (NMIBC) during the Bacillus Calmette\u2013Gu\u00e9rin shortage","volume":"30","author":"Fankhauser","year":"2020","journal-title":"Curr Opin Urol"},{"issue":"12","key":"10.1016\/j.urolonc.2021.03.024_bib0016","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1007\/s11934-019-0952-y","article-title":"Current clinical trials in non-muscle-invasive bladder cancer: Heightened need in an era of chronic BCG shortage","volume":"20","author":"Packiam","year":"2019","journal-title":"Curr Urol Rep"},{"issue":"1","key":"10.1016\/j.urolonc.2021.03.024_bib0017","doi-asserted-by":"crossref","first-page":"65","DOI":"10.3233\/BLC-150008","article-title":"Sequential intravesical gemcitabine and docetaxel for the salvage treatment of non-muscle invasive bladder cancer","volume":"1","author":"Steinberg","year":"2015","journal-title":"Bladder Cancer"},{"issue":"2","key":"10.1016\/j.urolonc.2021.03.024_bib0018","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1111\/j.1464-410X.1995.tb07307.x","article-title":"Analysis of early failures after intravesical instillation therapy with bacille Calmette-Guerin for carcinoma in situ of the bladder","volume":"75","author":"Merz","year":"1995","journal-title":"Br J Urol"},{"issue":"2 Part 1","key":"10.1016\/j.urolonc.2021.03.024_bib0019","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1016\/S0022-5347(17)32741-6","article-title":"Durability of the tumor-free response for intravesical bacillus calmette-guerin therapy","volume":"152","author":"Nadler","year":"1994","journal-title":"J Urol"},{"issue":"5","key":"10.1016\/j.urolonc.2021.03.024_bib0020","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1016\/S0090-4295(99)00591-9","article-title":"Long-term results of intravesical bacillus Calmette-Guerin therapy for stage T1 superficial bladder cancer","volume":"55","author":"Brake","year":"2000","journal-title":"Urology"},{"issue":"8","key":"10.1016\/j.urolonc.2021.03.024_bib0021","doi-asserted-by":"crossref","first-page":"1893","DOI":"10.1002\/cncr.24914","article-title":"Gemcitabine versus bacille calmette-guerin after initial bacille calmette-guerin failure in non-muscle-invasive bladder cancer: A multicenter prospective randomized trial","volume":"116","author":"Di Lorenzo","year":"2010","journal-title":"Cancer"},{"issue":"4","key":"10.1016\/j.urolonc.2021.03.024_bib0022","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1200\/JCO.2008.20.8199","article-title":"Randomized phase III trial on gemcitabine versus mytomicin in recurrent superficial bladder cancer: evaluation of efficacy and tolerance","volume":"28","author":"Addeo","year":"2010","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/j.urolonc.2021.03.024_bib0023","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/1078-1439(95)00041-F","article-title":"Randomized intergroup comparison of bacillus calmette-guerin immunotherapy and mitomycin C chemotherapy prophylaxis in superficial transitional cell carcinoma of the bladder a southwest oncology group study","volume":"1","author":"Lamm","year":"1995","journal-title":"Urol Oncol"},{"issue":"3","key":"10.1016\/j.urolonc.2021.03.024_bib0024","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1016\/j.juro.2012.10.068","article-title":"Long-term survival outcomes with intravesical docetaxel for recurrent nonmuscle invasive bladder cancer after previous bacillus Calmette-Guerin therapy","volume":"189","author":"Barlow","year":"2013","journal-title":"J Urol"},{"issue":"2","key":"10.1016\/j.urolonc.2021.03.024_bib0025","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1097\/01.ju.0000150425.09317.67","article-title":"Bacillus calmette-guerin versus epirubicin for primary, secondary or concurrent carcinoma in situ of the bladder: results of a european organization for the research and treatment of cancer\u2013genito-urinary group phase III trial (30906)","volume":"173","author":"de Reijke","year":"2005","journal-title":"J Urol"},{"issue":"3","key":"10.1016\/j.urolonc.2021.03.024_bib0026","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1111\/bju.13088","article-title":"Intravesical gemcitabine in combination with mitomycin C as salvage treatment in recurrent non-muscle-invasive bladder cancer","volume":"117","author":"Cockerill","year":"2016","journal-title":"BJU Int"},{"issue":"1","key":"10.1016\/j.urolonc.2021.03.024_bib0027","doi-asserted-by":"crossref","DOI":"10.1016\/j.urolonc.2013.01.009","article-title":"Multi-institutional analysis of sequential intravesical gemcitabine and mitomycin C chemotherapy for non-muscle invasive bladder cancer","volume":"32","author":"Lightfoot","year":"2014","journal-title":"Urol Oncol"},{"key":"10.1016\/j.urolonc.2021.03.024_bib0028","article-title":"Bacillus Calmette-Guerin strain may not effect recurrence-free survival when used intravesically with interferon-alpha2b for non-muscle-invasive bladder cancer","author":"Steinberg","year":"2016","journal-title":"Urol Oncol"}],"container-title":["Urologic Oncology: Seminars and Original Investigations"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1078143921001344?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1078143921001344?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T10:24:07Z","timestamp":1761042247000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1078143921001344"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1]]},"references-count":28,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,1]]}},"alternative-id":["S1078143921001344"],"URL":"https:\/\/doi.org\/10.1016\/j.urolonc.2021.03.024","relation":{},"ISSN":["1078-1439"],"issn-type":[{"value":"1078-1439","type":"print"}],"subject":[],"published":{"date-parts":[[2022,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Intravesical sequential gemcitabine and docetaxel versus bacillus calmette-guerin (BCG) plus interferon in patients with recurrent non-muscle invasive bladder cancer following a single induction course of BCG","name":"articletitle","label":"Article Title"},{"value":"Urologic Oncology: Seminars and Original Investigations","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.urolonc.2021.03.024","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}